Lab
Clinical Associates, LLC
Clinical Associates, LLC was paid $60.75M by Medicaid between Jan 2018 and Dec 2024, across 326 billing codes. Its largest line is 87591, Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe — 8.0% of everything it billed.
33Billing provider infoCLINICAL ASSOCIATES, LLC
LOUISVILLE, KY 40220
LOUISVILLE, KY 40220
33aNPI1881697464assigned 05/27/2005
33bProvider typeClinical Medical Laboratory
28Total paid$60.75M
24GClaims2,700,271
24DCodes billed326
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Clinical Medical Laboratory providers in Kentucky
Rank by total paid#2 of 73
Median peer was paid$95K
This provider vs. median640×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 260,347 | $6.22M | |
| 2019 | 321,325 | $7.95M | |
| 2020 | 384,917 | $10.17M | |
| 2021 | 455,036 | $9.24M | |
| 2022 | 455,062 | $10.19M | |
| 2023 | 453,978 | $9.25M | |
| 2024incomplete | 369,606 | $7.73M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | 8.0% | 138,884 | 130,629 | $4.87M |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | 8.0% | 138,734 | 130,624 | $4.87M |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | 6.8% | 120,485 | 114,487 | $4.11M |
| 81513 | 5.3% | 30,598 | 29,608 | $3.20M | |
| 87798 | Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism | 5.0% | 39,975 | 38,260 | $3.06M |
| 87481 | 4.2% | 64,959 | 37,798 | $2.53M | |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | 3.4% | 37,442 | 35,093 | $2.05M |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | 3.1% | 26,947 | 25,533 | $1.88M |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | 3.1% | 22,511 | 20,075 | $1.86M |
| 87637 | Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV | 2.8% | 13,346 | 12,562 | $1.70M |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | 2.8% | 70,660 | 68,496 | $1.70M |
| 88175 | Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer | 2.6% | 64,211 | 62,271 | $1.60M |
314 more codes
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc, making use of high throughput technologies as described by cms-2020-01-r | 2.5% | 22,320 | $1.54M |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | 2.2% | 187,823 | $1.33M |
| 87624 | Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types | 1.9% | 34,241 | $1.13M |
| 87086 | Culture, bacterial; quantitative colony count, urine | 1.8% | 137,149 | $1.07M |
| 84443 | Thyroid stimulating hormone (TSH) | 1.5% | 58,170 | $922K |
| 80053 | Comprehensive metabolic panel | 1.4% | 78,322 | $872K |
| 86803 | 1.3% | 54,316 | $800K | |
| 87633 | Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets | 1.2% | 2,605 | $745K |
| 86780 | 1.1% | 62,347 | $677K | |
| 82306 | Vitamin D; 25 hydroxy, includes fraction(s), if performed | 1.0% | 25,454 | $625K |
| 86481 | <1% | 6,533 | $562K | |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 22 or more drug class(es), including metabolite(s) if performed | <1% | 3,591 | $560K |
| 87340 | <1% | 47,041 | $489K | |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | <1% | 8,109 | $441K |
| 83516 | <1% | 12,194 | $424K | |
| 87653 | <1% | 13,009 | $416K | |
| 80074 | <1% | 10,874 | $355K | |
| 80061 | Lipid panel | <1% | 31,001 | $348K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 2,764 | $336K |
| 86762 | <1% | 22,360 | $322K | |
| 86003 | <1% | 4,053 | $314K | |
| 88342 | <1% | 9,268 | $313K | |
| 83021 | <1% | 17,237 | $304K | |
| 84702 | <1% | 19,616 | $298K | |
| 87186 | <1% | 34,897 | $291K | |
| 87070 | <1% | 28,962 | $286K | |
| 86787 | <1% | 21,636 | $280K | |
| 86850 | <1% | 26,141 | $267K | |
| 87077 | <1% | 33,030 | $267K | |
| 87522 | Neg quan hep c or qual rna | <1% | 6,237 | $267K |
| 84403 | <1% | 11,033 | $266K | |
| 36415 | Collection of venous blood by venipuncture | <1% | 72,476 | $260K |
| 82728 | <1% | 19,832 | $255K | |
| 88141 | <1% | 15,919 | $254K | |
| 84439 | <1% | 29,417 | $248K | |
| 81376 | <1% | 1,618 | $234K | |
| 87536 | <1% | 3,273 | $233K | |
| 81383 | <1% | 1,612 | $219K | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 32,836 | $217K |
| 83001 | <1% | 11,117 | $202K | |
| 88307 | <1% | 2,742 | $200K | |
| 84270 | <1% | 9,825 | $198K | |
| 86235 | <1% | 2,316 | $191K | |
| 87511 | <1% | 4,398 | $191K | |
| 82670 | <1% | 6,756 | $183K | |
| 84146 | <1% | 9,380 | $180K | |
| 83970 | <1% | 5,169 | $180K | |
| 83880 | <1% | 4,490 | $145K | |
| 82950 | <1% | 28,129 | $144K | |
| 86360 | <1% | 3,378 | $144K | |
| 82784 | <1% | 14,249 | $143K | |
| 87529 | <1% | 3,978 | $139K | |
| 84480 | <1% | 10,210 | $133K | |
| 83550 | <1% | 16,060 | $132K | |
| 83002 | <1% | 7,121 | $130K | |
| 84681 | <1% | 6,878 | $128K | |
| 86038 | <1% | 10,921 | $127K | |
| 88341 | <1% | 1,741 | $127K | |
| 82105 | <1% | 8,099 | $126K | |
| 86140 | <1% | 28,308 | $120K | |
| 86706 | <1% | 11,779 | $117K | |
| 82607 | <1% | 8,182 | $114K | |
| 85027 | <1% | 18,123 | $113K | |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 15-21 drug class(es), including metabolite(s) if performed | <1% | 701 | $111K |
| 87088 | <1% | 13,778 | $107K | |
| 83540 | <1% | 16,638 | $102K | |
| 86160 | <1% | 4,495 | $101K | |
| 86376 | <1% | 7,368 | $101K | |
| 86147 | <1% | 1,908 | $88K | |
| 84402 | <1% | 3,781 | $81K | |
| 86480 | <1% | 1,119 | $81K | |
| 86146 | <1% | 1,646 | $80K | |
| 86334 | <1% | 5,341 | $79K | |
| 82627 | <1% | 3,763 | $78K | |
| 85652 | <1% | 31,954 | $77K | |
| 86800 | <1% | 5,138 | $76K | |
| 87581 | <1% | 2,618 | $76K | |
| 87486 | <1% | 2,613 | $76K | |
| 83013 | <1% | 1,100 | $74K | |
| 84165 | <1% | 8,435 | $73K | |
| 83655 | <1% | 6,585 | $70K | |
| 84305 | <1% | 3,667 | $70K | |
| 86900 | <1% | 22,958 | $69K | |
| 83498 | <1% | 2,747 | $69K | |
| 86901 | <1% | 22,945 | $69K | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 8,417 | $67K |
| 82570 | <1% | 14,353 | $67K | |
| 81001 | <1% | 22,264 | $63K | |
| 88189 | <1% | 961 | $62K | |
| 87081 | <1% | 7,570 | $59K | |
| 88377 | <1% | 771 | $58K | |
| 82024 | <1% | 1,823 | $57K | |
| 84445 | <1% | 1,310 | $57K | |
| 86704 | <1% | 5,407 | $56K | |
| 80069 | <1% | 7,399 | $55K | |
| 86200 | <1% | 3,964 | $50K | |
| 82533 | <1% | 3,096 | $47K | |
| 87046 | <1% | 2,520 | $46K | |
| 86431 | <1% | 7,433 | $44K | |
| 86665 | <1% | 1,596 | $43K | |
| 86695 | <1% | 2,721 | $42K | |
| 84156 | <1% | 12,432 | $41K | |
| 86696 | <1% | 2,406 | $41K | |
| 88360 | <1% | 627 | $40K | |
| 86664 | <1% | 1,586 | $36K | |
| 84207 | <1% | 1,540 | $36K | |
| 85007 | <1% | 11,418 | $35K | |
| 85610 | <1% | 8,825 | $35K | |
| 82746 | <1% | 2,557 | $35K | |
| 84460 | <1% | 7,426 | $35K | |
| 86769 | <1% | 1,333 | $35K | |
| 84450 | <1% | 7,185 | $33K | |
| 84432 | <1% | 2,190 | $33K | |
| 82565 | <1% | 6,855 | $31K | |
| 86225 | <1% | 2,514 | $31K | |
| 86039 | <1% | 2,657 | $30K | |
| 87427 | <1% | 2,493 | $30K | |
| 88304 | <1% | 2,302 | $30K | |
| 85240 | <1% | 1,643 | $30K | |
| 80076 | <1% | 3,462 | $29K | |
| 87493 | <1% | 880 | $29K | |
| 84144 | <1% | 1,364 | $29K | |
| 82397 | <1% | 2,123 | $28K | |
| 86592 | <1% | 6,785 | $28K | |
| 84481 | <1% | 1,644 | $28K | |
| 87177 | <1% | 3,080 | $26K | |
| 83020 | <1% | 3,114 | $26K | |
| 81241 | <1% | 504 | $25K | |
| 87045 | <1% | 2,642 | $25K | |
| 82638 | <1% | 1,711 | $25K | |
| 84153 | <1% | 1,521 | $24K | |
| 82550 | <1% | 3,779 | $24K | |
| 86708 | <1% | 2,146 | $24K | |
| 86757 | <1% | 1,288 | $23K | |
| 81003 | <1% | 10,854 | $22K | |
| 85730 | <1% | 4,969 | $22K | |
| 88182 | <1% | 750 | $21K | |
| 83735 | <1% | 3,468 | $21K | |
| 86663 | <1% | 1,588 | $21K | |
| 82610 | <1% | 1,281 | $20K | |
| 84425 | <1% | 1,083 | $19K | |
| 87338 | <1% | 1,460 | $19K | |
| 80050 | General health panel | <1% | 611 | $19K |
| 81220 | CFTR (cystic fibrosis transmembrane conductance regulator) gene analysis; common variants | <1% | 161 | $19K |
| 86341 | <1% | 1,035 | $18K | |
| 86812 | <1% | 787 | $18K | |
| 87902 | <1% | 69 | $18K | |
| 85613 | <1% | 1,821 | $17K | |
| 82977 | <1% | 2,589 | $17K | |
| 86694 | <1% | 1,163 | $17K | |
| 82947 | <1% | 4,025 | $16K | |
| 87184 | <1% | 2,048 | $15K | |
| 81511 | <1% | 145 | $14K | |
| 83519 | <1% | 640 | $13K | |
| 82677 | <1% | 470 | $13K | |
| 86256 | <1% | 1,032 | $13K | |
| 82043 | <1% | 2,557 | $13K | |
| 83520 | <1% | 623 | $13K | |
| 83525 | <1% | 1,379 | $13K | |
| 81240 | <1% | 349 | $13K | |
| 82785 | <1% | 677 | $12K | |
| 86328 | <1% | 333 | $12K | |
| 83690 | <1% | 1,781 | $12K | |
| 85670 | <1% | 2,082 | $12K | |
| 82310 | <1% | 2,574 | $12K | |
| 85390 | <1% | 1,003 | $12K | |
| 85244 | <1% | 600 | $12K | |
| 85045 | <1% | 2,642 | $11K | |
| 83921 | <1% | 689 | $11K | |
| 85245 | <1% | 429 | $11K | |
| 86336 | <1% | 632 | $11K | |
| 84100 | <1% | 2,466 | $11K | |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 120 | $11K |
| 84550 | <1% | 2,339 | $10K | |
| 85246 | <1% | 384 | $10K | |
| 83615 | <1% | 1,666 | $10K | |
| 82951 | <1% | 570 | $9K | |
| 86617 | <1% | 393 | $9K | |
| 82239 | <1% | 630 | $9K | |
| 83876 | <1% | 219 | $9K | |
| 87205 | <1% | 2,234 | $9K | |
| 83090 | <1% | 509 | $9K | |
| 85018 | <1% | 3,616 | $9K | |
| 81050 | <1% | 2,322 | $9K | |
| 86618 | <1% | 637 | $8K | |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | <1% | 361 | $8K |
| 82150 | <1% | 1,264 | $8K | |
| 80164 | <1% | 682 | $8K | |
| 85014 | <1% | 3,282 | $8K | |
| 87625 | <1% | 267 | $8K | |
| 83993 | <1% | 513 | $7K | |
| 86682 | <1% | 643 | $7K | |
| 82103 | <1% | 680 | $7K | |
| 86593 | <1% | 1,723 | $7K | |
| 82747 | <1% | 477 | $7K | |
| 85247 | <1% | 283 | $7K | |
| 87329 | <1% | 567 | $6K | |
| 82088 | <1% | 205 | $6K | |
| 87535 | <1% | 135 | $6K | |
| 86870 | <1% | 536 | $6K | |
| 84703 | <1% | 752 | $5K | |
| 82157 | <1% | 224 | $5K | |
| 82340 | <1% | 1,065 | $5K | |
| 82652 | <1% | 198 | $5K | |
| 86765 | <1% | 389 | $5K | |
| 84244 | <1% | 302 | $5K | |
| 86666 | <1% | 326 | $5K | |
| G0452 | Molecular pathology procedure; physician interpretation and report | <1% | 673 | $5K |
| 82085 | <1% | 532 | $5K | |
| 84436 | <1% | 824 | $5K | |
| 82390 | <1% | 595 | $5K | |
| 88112 | <1% | 95 | $4K | |
| 87328 | <1% | 337 | $4K | |
| 80150 | <1% | 480 | $4K | |
| 84630 | <1% | 407 | $4K | |
| 82248 | <1% | 796 | $4K | |
| 85379 | <1% | 361 | $3K | |
| 80299 | <1% | 347 | $3K | |
| 87517 | <1% | 100 | $3K | |
| 86735 | <1% | 237 | $3K | |
| 87075 | <1% | 354 | $3K | |
| 85660 | <1% | 555 | $3K | |
| 83835 | <1% | 232 | $3K | |
| 87324 | <1% | 208 | $3K | |
| 86705 | <1% | 215 | $3K | |
| 82671 | <1% | 120 | $3K | |
| 86359 | <1% | 73 | $2K | |
| 86355 | <1% | 70 | $2K | |
| 82180 | <1% | 310 | $2K | |
| 83721 | <1% | 193 | $2K | |
| 80081 | <1% | 47 | $2K | |
| 88185 | <1% | 13 | $2K | |
| 84110 | <1% | 180 | $2K | |
| 84446 | <1% | 178 | $2K | |
| 87901 | <1% | 15 | $2K | |
| 86141 | <1% | 125 | $2K | |
| 86317 | <1% | 53 | $2K | |
| 80177 | <1% | 220 | $2K | |
| 86644 | <1% | 121 | $2K | |
| 82952 | <1% | 3,392 | $2K | |
| 86255 | <1% | 226 | $2K | |
| 86357 | <1% | 52 | $2K | |
| 88188 | <1% | 29 | $2K | |
| 87350 | <1% | 123 | $2K | |
| 84590 | <1% | 171 | $2K | |
| 87651 | Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe | <1% | 47 | $2K |
| 80197 | <1% | 131 | $1K | |
| 81025 | <1% | 238 | $1K | |
| 84484 | <1% | 148 | $1K | |
| 80348 | <1% | 954 | $1K | |
| 88381 | <1% | 40 | $1K | |
| 86645 | <1% | 73 | $1K | |
| 82525 | <1% | 146 | $1K | |
| 87102 | <1% | 171 | $1K | |
| 82164 | <1% | 87 | $1K | |
| 81270 | <1% | 16 | $1K | |
| 88313 | <1% | 28 | $1K | |
| 88142 | <1% | 58 | $1K | |
| 87900 | <1% | 15 | $1K | |
| 85049 | <1% | 196 | $984.01 | |
| 87040 | <1% | 158 | $967.23 | |
| 87799 | <1% | 30 | $948.65 | |
| 86698 | <1% | 45 | $943.46 | |
| 84478 | <1% | 185 | $931.91 | |
| 85303 | <1% | 69 | $854.83 | |
| 82104 | <1% | 71 | $852.21 | |
| 82247 | <1% | 124 | $754.06 | |
| 80202 | <1% | 60 | $712.40 | |
| 85384 | <1% | 63 | $674.78 | |
| 84143 | <1% | 27 | $631.61 | |
| 80183 | <1% | 57 | $548.83 | |
| 87185 | <1% | 248 | $544.25 | |
| 82172 | <1% | 33 | $496.83 | |
| 80343 | <1% | 109 | $486.00 | |
| 83010 | <1% | 52 | $465.14 | |
| 87400 | <1% | 17 | $459.71 | |
| 86747 | <1% | 13 | $453.39 | |
| 86337 | <1% | 24 | $452.25 | |
| 88164 | <1% | 35 | $423.72 | |
| 86008 | <1% | 39 | $412.92 | |
| 85306 | <1% | 28 | $411.55 | |
| 85048 | <1% | 133 | $393.33 | |
| 85576 | <1% | 15 | $380.13 | |
| 86709 | <1% | 32 | $373.56 | |
| 85300 | <1% | 35 | $364.28 | |
| 83527 | <1% | 32 | $341.55 | |
| 86668 | <1% | 12 | $311.23 | |
| 84466 | <1% | 24 | $287.16 | |
| 88302 | <1% | 64 | $278.77 | |
| 82384 | <1% | 14 | $267.91 | |
| 86304 | <1% | 13 | $241.82 | |
| 88184 | <1% | 12 | $205.20 | |
| 82540 | <1% | 54 | $202.56 | |
| 83883 | <1% | 21 | $200.34 | |
| 83630 | <1% | 12 | $194.24 | |
| 86606 | <1% | 16 | $181.35 | |
| 82378 | <1% | 14 | $171.89 | |
| 80178 | <1% | 26 | $170.57 | |
| 82465 | <1% | 39 | $168.71 | |
| 84704 | <1% | 15 | $166.39 | |
| 83695 | <1% | 14 | $153.66 | |
| 86774 | <1% | 12 | $153.38 | |
| 84075 | <1% | 32 | $152.82 | |
| 87116 | <1% | 20 | $149.35 | |
| 87206 | <1% | 35 | $136.36 | |
| 36416 | <1% | 162 | $128.59 | |
| 82955 | <1% | 13 | $120.28 | |
| 86886 | <1% | 13 | $100.45 | |
| 87015 | <1% | 19 | $83.43 | |
| G0472 | Hepatitis c antibody screening, for individual at high risk and other covered indication(s) | <1% | 281 | $79.73 |
| 83051 | <1% | 17 | $58.85 | |
| 82270 | <1% | 12 | $45.02 | |
| G0145 | Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision | <1% | 417 | $29.09 |
| 81479 | Unlisted molecular pathology procedure | 0% | 17 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialROWAN, DIANNE (DIRECTOR FINANCE BILLING)
Parent organizationNORTON ENTERPRISES INC
| Provider | Location | Paid |
|---|---|---|
| Clinical Associates LLC | Louisville, KY | $0.00 |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.